title: Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.
abstract: OBJECTIVE
  We performed a randomised controlled study regarding the effects of androgen replacement therapy (ART) on lower urinary tract symptoms (LUTS) in hypogonadal men with benign prostate hypertrophy (BPH).
  
  
  METHODS
  Fifty-two patients with hypogonadism and BPH were randomly assigned to receive testosterone (ART group) as 250 mg of testosterone enanthate every 4 weeks or to the untreated control group. We compared International Prostate Symptom Score (IPSS), uroflowmetry data, post-voiding residual volume (PVR) and systemic muscle volume at baseline and 12 months after treatment.
  
  
  RESULTS
  Forty-six patients (ART group, n=23; control, n=23) were included in the analysis. At the 12-month visit, IPSS showed a significant decrease compared with baseline in the ART group (15.7 +/- 8.7 vs. 12.5 +/- 9.5; p<0.05). No significant changes were observed in the control group. The ART group also showed improvement in maximum flow rate and voided volume (p<0.05), whereas no significant improvements were observed in the controls. PVR showed no significant changes in either group. In addition, the ART group showed significant enhancement of mean muscle volume (p<0.05), whereas no significant changes were seen in the controls.
  
  
  CONCLUSIONS
  ART improved LUTS in hypogonadal men with mild BPH.
authors.affiliation: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan. kshigehara0415@yahoo.co.jp
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Shigehara
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Konaka
authors.forename: Masashi
authors.initials: M
authors.lastname: Iijima
authors.forename: Masato
authors.initials: M
authors.lastname: Fukushima
authors.forename: Yuji
authors.initials: Y
authors.lastname: Maeda
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.forename: Eitetsu
authors.initials: E
authors.lastname: Koh
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
authors.forename: Teruaki
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000367:Age Factors; D000368:Aged; D000375:Aging; D000728:Androgens / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D018450:Disease Progression; D006305:Health Status Indicators; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy*; D008297:Male; D054526:Men's Health; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D013739:Testosterone / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use*; D014563:Urodynamics; D014570:Urologic Diseases / Q000097:blood / Q000188:drug therapy*
chemical_list: D000728:Androgens; D013739:Testosterone